Roche Holding AG

Roche Holding AG logo
🇨🇭Switzerland
Ownership
Public
Established
1896-01-15
Employees
103.6K
Market Cap
$270.5B
Website
http://www.roche.com
Clinical Trials
Related News

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.

First Posted Date
2007-01-19
Last Posted Date
2016-05-09
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
20
Registration Number
NCT00424502

A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Phase 2
Completed
Conditions
Diabetes Mellitus Type 2
Interventions
Drug: taspoglutide
Drug: Placebo
First Posted Date
2007-01-18
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
306
Registration Number
NCT00423501

A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)

First Posted Date
2007-01-17
Last Posted Date
2014-07-16
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
3
Registration Number
NCT00422942

A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)

Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: rituximab [MabThera/Rituxan]
First Posted Date
2007-01-17
Last Posted Date
2015-05-04
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
378
Registration Number
NCT00422383

A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

First Posted Date
2007-01-17
Last Posted Date
2011-12-14
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
260
Registration Number
NCT00422513

A Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients Switched From EC-MPS.

Phase 4
Terminated
Conditions
Kidney Transplantation
First Posted Date
2007-01-11
Last Posted Date
2007-11-20
Lead Sponsor
Hoffmann-La Roche
Registration Number
NCT00420472

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

First Posted Date
2006-12-20
Last Posted Date
2016-02-15
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
424
Registration Number
NCT00413894

A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.

Phase 4
Completed
Conditions
Anemia
Interventions
Drug: epoetin beta [NeoRecormon]
First Posted Date
2006-12-19
Last Posted Date
2009-05-14
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
50
Registration Number
NCT00413101

TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)

Phase 2
Completed
Conditions
Emphysema
Interventions
Drug: RAR Gamma
Drug: Placebo
First Posted Date
2006-12-19
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
491
Registration Number
NCT00413205

A Study of Tamiflu (Oseltamivir) for Seasonal Prophylaxis of Influenza in Children.

Phase 4
Completed
Conditions
Influenza
Interventions
Drug: oseltamivir [Tamiflu]
First Posted Date
2006-12-18
Last Posted Date
2020-08-18
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
52
Registration Number
NCT00412555
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy